Find Faculty
Home>Find Faculty>Christopher L. Coogan, MD

Christopher L. Coogan, MD

Urology Residency Program Director
Professor, Department of Urology, RUSH Medical College
Education

MD, Rush Medical College
MS, Emory University
BA, Lawrence University
Fellowship, Indiana University School of Medicine

Areas of Expertise

Benign prostatic hyperplasia (BPH), bladder cancer, hematuria (blood in urine), kidney cancer, kidney stones, nephrectomy, prostate cancer, prostatectomy, robotic surgery, testicular cancer

Contact Info:

Rush Urology - Oak Park
610 South Maple Ave.
Rush Medical Office Building
Suite 3450
Oak Park, IL, 60304
Phone: (708) 660-2422
Fax: (708) 660-2421


 
Links:
Biography

Christopher Coogan, MD, is a professor of urology and residency program director at Rush University. He attended medical school and residency at Rush, followed by a fellowship in urological oncology at Indiana University. Coogan specializes in urological cancers, including prostate, kidney, bladder and testis. He performs minimally invasive surgery when appropriate including robotic and laparoscopic surgery. He also has extensive experience in treating voiding complaints/BPH and kidney stones. He has remained at Rush since 1996 and has authored or co-authored more than 65 journal articles or book chapters. He is a past president of the Chicago Urological Society, fellow of the American College of Physicians, AUA and NCS. He also is current treasurer of Illinois State Urological Society.  

Honors and Activities
  • 2012 - 1st place, Irving J. Shapiro X-ray Conference, Chicago Urological Society: Coogan CL and Benson, J, Duplicated Kidney in a Scrotal Mass
  • 2011 - 2nd Place, Charles Huggins Resident Essay Contest, Chicago Urological Society, Coogan CL and Abern M: Radiation Therapy Increases the Risk of Bladder Cancer, January 2011
  • 2010 - 2nd Place, Irving J. Shapiro X-ray Conference, Chicago Urological Society, Coogan CL and Taylor R: Dedifferentiated Liposarcoma of the Kidney Weighing 22 lbs
  • 2009 - 2nd Place, Irving J. Shapiro X-ray Conference, Chicago Urological Society, Coogan CL and Taylor R: Neuroendocrine Tumor of the Testicle
  • 2006 - 4th Place, Rush Surgical Society Contest, Rush University Medical Center, Coogan CL, Strom K: Urology in States With and Without NED (non-economic damage), May 2006
  • 2006 - 3rd Place, Charles P. Huggins Resident Essay Contest, Chicago Urological Society, Coogan CL, Strom K: Urology in States with and Without NED (non-economic damages) January 2006
  • 2003 - 2nd Place, Charles P. Huggins Resident Essay Contest, Chicago Urological Society, Coogan CL, Estrada CR, Kapur S and Bloom KJ: HER-2NEU Receptor Protein Over-Expression and Gene Amplification in Transitional Cell Carcinoma of the Bladder.
  • 2000 - 1st Place, Irving J. Shapiro X-ray Conference, Chicago Urological Society, Coogan CL and Dimitriou R: Penile Cancer in a Genetic Female with Congenital Adrenal Hyperplasia
  • 1999 - 1st Place, Irving J. Shapiro X-ray Conference, Chicago Urological Society: Coogan CL and Ellterman L: Metanephric Adenoma: Case Presentation and Review of Literature

1st Place, Irving J. Shapiro X-ray Conference, Chicago Urological Society, Coogan CL and Dimitriou, R: Carcinosarcoma: Case Study and Review of Literature

  • 1998 - Irving J. Shapiro Award for Outstanding Service and Teaching, Chicago Urological Society
  • 1997 - 3rd Place, Irving J. Shapiro X-ray Conference, Chicago Urological Society, Coogan CL and Elterman L: Multiocular Cyst; Case Report and Review of Literature
  • 1997 - Specialty Surgical Attending Award for Outstanding Contribution to Resident Education, Rush-Presbyterian-St. Luke’s Medical Center
  • 1993 - 2nd Place, Clinical Research, Charles B. Huggins Resident Essay Conference, Chicago Urological Society, Coogan and Levine LA: Penile Vascular Assessment Using Color Duplex Sonography in Men with Peyronie’s Disease
  • 1993 - 2nd Place, Irwin J. Shapiro X-ray Conference, Chicago Urological Society, Coogan CL and Bormes TP: Malakoplakia; Case Presentation and Review of Literature
  • 1990 - MD (top 20) Rush Medical College
  • 1984 - BA, Cum Laude, Lawrence University, Appleton, WI
Grants
  • 2015 - Dean’s Proposal, A comparative Analysis of TRUS Biopsy versus MRI Fusion Biopsy at Determining Prostate. Cancer Pathology
  • 2015 - Co-Investigator: The Current State of Medical Malpractice in Urology. 2015 Elsevier
  • 2012 - Current: Co-Investigator: AGS-003-007: An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced RCC
  • 2011-2014: Fibroblast Growth Factor Receptors in Bladder Cancer: A Novel Tumor Marker
  • 2010-2012:  Hot Flashes and Memory in Men on Depot GNRH for CAP. Currently enrolling patients and in conjunction with UIC investigating the potential loss of memory in men treated with LHRH agonist for Prostate Cancer.
  • 2007-2010:  Principal Investigator: Phase II Trial of Soy Prior to Radical Prostatectomy (Funded by NCI, in collaboration with UIC/ NYU School of Medicine).
  • 2006-2008:  Co- Investigator: Detection of Prostate and Bladder Cancer by DNA Methylation in Serum and Urine.  In conjunction with ABBOTT in an attempt to develop a novel marker for bladder and prostate cancer.
  • 2002-2004  Principal Investigator:  “Pain Perception and Immune Function During The Perioperative Radical Prostatectomy Experience:  A Psychonueroimmunological (Mind/Body) Approach
  • 2000-current: Endoscopic Treatment of VesicoUreteral Reflux in Transplant Patients with Urinary Tract Infection.  This was a novel idea in transplant recipients and first presented and published by Dr Coogan.
  • 2001-2002:  Co Investigator:  “A Double-Blind Placebo-Controlled Parallel-Group Safety and Efficacy Study Evaluation Three Doses Regimens of AIO-8507L, A Selective Alpha-Adrenergic Antagonist, In the Treatment of Benign Prostatic Hyperplasia”
  • 1999-2000: Principal Investigator:  “Randomized Double-Blinded Placebo-controlled Two Year Parallel Group Study of the Efficacy and Safety of GII98745 (Avodart®) 0.5 mgs. in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia—Extension
  • 1997-1998:  Principal Investigator: “An Open Label 12 Month Trial of Oral Phentolamine in Patients with Mild-to-Moderate Erectile Dysfunction”. I enrolled the most number of patients in the country involving 37 sites and 2478 patients.
  • 1997-1998: Principal Investigator:  “Randomized Double-Blinded Placebo-controlled Two Year Parallel Group Study of the Efficacy and Safety of GII98745 (Avodart®) 0.5 mgs in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia” Lead to FDA approval of Avodart with 4,325 patients randomized in a multicenter trial
  • 1996-1999:  Investigator:  “SWOG-9217, Chemoprevention of Prostate Cancer with Finasteride (Proscar®), Phase III, Intergroup” Prostate cancer prevention trial with 18,000 patients.